论文部分内容阅读
高三尖杉酯碱治疗急性非淋巴细胞性白血病(以下简称非淋急白)有效,已经国内临床证实。为进一步探索具有高效低毒的联合化疗方案,我院血液病研究室于1977年11月设计了由高三尖杉酯碱、长春新碱、阿糖胞苷及强的松联合的HOAP(Homoharringtonin,Vinc-ristin,Cytosine Arabinoside,Prednisone)方案。近一年来,对非淋急白的初治者进行了试验性治疗,现将满三个疗程的8例成人、2例儿童,共计10例的资料进行初步小结。
Homoharringtonine for the treatment of acute non-lymphocytic leukemia (hereinafter referred to as non-leaching emergency) effective, has been clinically confirmed. In order to further explore the combination of chemotherapy with high efficiency and low toxicity, our hospital blood disease laboratory in November 1977 designed a combination of homoharringtonine, vincristine, cytarabine and prednisone HOAP (Homoharringtonin, Vinc-ristin, Cytosine Arabinoside, Prednisone) protocol. Nearly a year, the treatment of non-leukemia naive experimental treatment, now full of three courses of 8 adults, 2 children, a total of 10 cases of the data summary.